Invasive fungal diseases (IFDs) are a leading cause of morbidity and infection-related mortality among allogeneic hematopoietic stem cell transplantation (HSCT) recipients [1, 2]. In recent years, advanced diagnostic tests have considerably improved the diagnosis of IFD, but the standard methods often fail to timely detect the fungal pathogen and are not suitable for regular monitoring of an infection [3]. The routine evaluation with chest radiography has several limitations due to the following: low sensitivity, patient condition, time consumption, and inter-observer variability in its interpretation [4, 5]. On the contrary, computed tomography (CT) is considered the gold standard technique, but may not be available in the due time; it involves a high radiation dose and relatively high cost [6]. The lungs are considered poorly accessible to ultrasound (US) investigation because of their air content. Only in the last decade, it has been shown that the US assessment of the lung could have clinical implications [7]. The lung US is increasingly applied owing to its application in rapid diagnosis and management of critically ill patients [8]. The purpose of this study was to investigate the application of lung US in the evaluation of IFD in hematological patients undergoing allogeneic HSCT.

In this prospective non-interventional study, bedside lung US examination was longitudinally performed in patients with IFD undergoing allogeneic HSCT, at diagnosis and 10 days after...
the start of antifungal treatment. This pilot study was approved by local ethical committee (IRB’s audit number:103/INT/2015) and written informed consent was obtained from all patients. Anti-infectious prophylaxis and treatment were administered according to institutional guidelines, based on international recommendations.

Within an 18-month recruitment period, 10 consecutive patients who developed an IFD after allogeneic HSCT were included in this pilot study. All evaluable patients had an established diagnosis of IFD according to the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) definitions [3]. Computed tomography scan was used to diagnose fungal pneumonia, following the radiological patterns defined by the EORTC/MSG definitions [3].

Convex 3.5 to 5 MHz probes (Logiq F6 model, portable device; GE Healthcare, Milan, Italy) were used. Two skilled physicians performed all study examinations. At bedside, the probe was set perpendicular, oblique, and parallel to the ribs in the anterior, lateral, and posterior (lower and upper) thorax. Sitting position and lateral decubitus were used to scan the posterior chest wall. Each hemithorax was divided into five areas [9]: 2 anterior, 2 lateral, and 1 posterior. The anterior chest wall was marked off from the parasternal line to the anterior axillary line. This zone was divided into an upper region (from the collarbone to the second-third intercostal space) and a lower region (from the third intercostal space to the diaphragm). Furthermore, the lateral area, from the anterior to the posterior axillary lines, was divided into upper and lower halves. Finally, the posterior zone was demarcated from the posterior axillary line to the paravertebral line.

The criterion to determine the echographic diagnosis of pneumonia was the finding of subpleural lung consolidation with evidence of static or dynamic air bronchograms. Vertically oriented “comet-tail” artifacts, B lines [10], might be present. We used the dynamic US signs for the differential diagnosis of pneumonia with pulmonary atelectasis, characterized by a liver-like appearance of the lung with “lung pulse” (absence of lung sliding and a parallel course of air).

The patients (median age 44.5 y) underwent allogeneic HSCT for high-risk hematological malignancies (6 with acute leukemia, 1 with chronic myeloid leukemia, 1 with Hodgkin lymphoma, and 1 with non-Hodgkin lymphoma); 50% of the patients were not in complete remission during transplantation. Stem cell donors were family haploidentical (n = 6), human leucocyte antigen identical sibling (n = 2), and unrelated volunteer (n = 2). The stem cell source was T-cell replete peripheral blood stem cells. All patients received a treosulfan-based conditioning regimen and graft-versus-host disease prophylaxis with post-transplant cyclophosphamide and sirolimus [11, 12].

Early after HSCT (before neutrophil engraftment), we documented 8 possible and 2 probable pulmonary IFDs (Table 1). Posaconazole was used as the antifungal therapy in 2 cases, voriconazole in 2, isavuconazole in 2, and a combination of liposomal amphotericin plus azole in 4.

The lung US (Fig. 1 and Supplementary Fig. 1) was performed in all cases, concomitantly with high-resolution CT scan (Fig. 2). A complete examination required 10 (10 - 15) min. The investigators judged examination conditions as “good” in all cases except one, which was...
Table 1. Diagnosis of IFD according to the EORTC/MSG definitions

| IFD (EORTC/MSG) | Imaging criteria | Clinical criteria | Mycological criteria | Prophylaxis | Therapy |
|-----------------|------------------|-------------------|----------------------|-------------|---------|
| UPN 1 Possible  | Bilateral nodular ground-glass lesions (inferior lobes) | Fever + pneumonia + neutropenia + previous possible IFD + steroid therapy | Galactomannan negative | Micafungin | Posaconazole |
| UPN 2 Possible  | Nodular cavitary lesion in superior left lobe | Fever + pneumonia + steroid therapy | Negative | Voriconazole | Voriconazole + amphotericin B |
| UPN 3 Possible  | Bilateral nodular ground-glass lesions, two nodular lesions in inferior left lobe and one in upper right lobe | Fever + pneumonia + neutropenia + previous probable IFD | Negative | Posaconazole | Voriconazole + amphotericin B |
| UPN 4 Probable  | Nodular ground-glass lesions, one nodular lesion in superior left lobe and two in medium left lobe | Fever + pneumonia + neutropenia + previous possible IFD | Positive (BAL) | Voriconazole | Posaconazole |
| UPN 5 Possible  | Nodular lesion in medium lobe (cavity inside) | Fever + pneumonia + neutropenia + previous probable IFD | Negative | Voriconazole | Voriconazole + amphotericin B |
| UPN 6 Probable  | Nodular ground-glass lesions (bilateral) | Fever + pneumonia + neutropenia + previous probable IFD | Positive (BAL) | Amphotericin B | Voriconazole |
| UPN 7 Possible  | Nodular lesion in medium right lobe, multiple bilateral nodular ground-glass lesions, pleural effusion (right > left) | Fever + pneumonia + neutropenia + previous probable IFD | Negative | Amphotericin B | Voriconazole |
| UPN 8 Possible  | Nodular lesion in left superior lobe (partial cavity inside) > nodular lesion in right superior lobe | Fever + pneumonia + previous probable IFD | Negative | Voriconazole | Isavuconazole + amphotericin B |
| UPN 9 Possible  | Bilateral nodular ground-glass lesions (inferior lobes) | Fever + pneumonia + neutropenia + previous probable IFD + steroid therapy | Negative | Micafungin | Isavuconazole |
| UPN 10 Possible | Bilateral nodular ground-glass lesions (left > right); minimum pleural effusion (left) | Fever + pneumonia + neutropenia + steroid therapy | Negative | Voriconazole | Isavuconazole |

IFD, invasive fungal disease; EORTC/MSG, European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group; BAL, bronchoalveolar lavage.

Figure 1. Lung ultrasound images and concomitant computed tomography scan images (UPN 7, UPN 8, and UPN 9). (A) Evidence of a consolidated hypoechoic area with positive air bronchogram in the right medium lobe; presence of a contiguous moderate pleural effusion (patient UPN 7). (A') Nodular lesion in the medium right lobe and pleural effusion (right > left; patient UPN 7). (B) A consolidated hypoechoic area in the left superior lobe with pleural line attenuation corresponding to the affected area (patient UPN 8). (B') Nodular lesion in the left superior lobe (partial cavity inside; air crescent sign) and a smaller nodular lesion in the right superior lobe (patient UPN 8). (C) Presence of small consolidated hypoechoic areas with positive air bronchogram sign and contiguous focal B lines in the left inferior lobe (patient UPN 9). (C') Bilateral nodular ground-glass lesions (inferior lobes; patient UPN 9).
considered “limited” due to poor patient compliance. The most important parenchymal US criterion was the positive air bronchogram within a hypoechoic area, which was found in 40% of the patients, and the most frequent pleural criterion was basal effusion (in 40% patients). At diagnosis, patients showed consolidations, hypoechoic areas, and an inhomogeneous echotexture with blurred margins, most frequently on both sides of the lungs (n = 7), rather than on the right (n = 1) or left (n = 2) side of the lungs.

Four patients presented a positive air bronchogram, reflecting residual air within consolidated areas and attesting bronchial patency, which ruled out obstructive atelectasis. Multiple lenticular echoes, representing air trapped in the smaller airways, were also observed in these patients. No fluid bronchogram was observed. Contiguous focal B-lines and a pleural line attenuation corresponding to the affected area were evident in eight patients. Pleural basal effusion was detected in four patients, appearing as an anechoic area in the pleural space.

During follow up, we documented a clinical improvement, which was also demonstrated by CT scan and lung US (Fig. 1), in all patients except one. Pneumonic lesions appeared sonographically smaller and the volume of pleural effusion decreased in patients with a documented IFD response. Importantly, all US findings were comparable to the CT scan results (Fig. 1 and 2). Correlations with CT images showed that B lines were related to the presence of interstitial syndrome [7]. We did not observe any discrepancy in US findings between the two physicians.

Invasive fungal diseases continue to cause considerable morbidity and mortality in patients with hematological malignancy. Given the poor outcomes associated with IFD in transplant recipients, there is considerable interest in identifying early bedside diagnostic and prognostic tools that may help guide the development of tailored intervention strategies.

Figure 2. Lung ultrasound images and concomitant computed tomography scan images (UPN 2, UPN 3, and UPN 10). (D) Evidence of a small consolidated hypoechoic area in the left superior lobe with pleural line attenuation corresponding to the affected area (patient UPN 2). (D’) Nodular lesion in the superior left lobe (cavity inside; patient UPN 2). (E) One nodular cavitary lesion in the inferior left lobe (patient UPN 3). (E’) Two consolidated hypoechoic areas in the inferior left lobe (patient UPN 3). (F) Bilateral nodular ground-glass lesions (left > right; patient UPN 10). (F’) A scan taken 10 days after the start of antifungal treatment showed smaller consolidated hypoechoic areas in the left inferior lobe and reduction of pleural effusion in comparison to the examination at diagnosis (patient UPN 10).
The lung US is considered a promising technique owing to its high sensitivity in the detection of lung lesions and in the follow-up examinations, with the advantages of being cost effective and time saving. The main advantages of bedside lung US include postponing or even avoiding transport of patients to the radiology unit (also preventing radiation exposure of CT scan) and guiding life-saving therapies in extreme emergencies. Most US devices are portable or hand held, and may be used in critical care situations and in patients in a semi-recumbent or supine position. However, the ability of US to detect general abnormalities in the lung rather than peculiar IFD signs as captured by CT scan, suggest US as a potential tool during the follow up of lung IFDs instead of its diagnosis.

The lung US was at least as good as X-ray evaluation in detecting pneumonia [13]. Sonography can detect peripheral pneumonic lesions, even small ones, whereas X-ray covers central localized processes, but small ones may escape radiological detection. During the follow up, the lung US may appear normal because the lesions do not reach the peripheral pleura. Another possible limitation of US is the variation in its accuracy between different examiners, depending on the skill of the examiner. To overcome this variability, two skilled physicians performed all examinations in this study.

Moreover, the low rates of probable pulmonary IFDs and the predominance of possible IFDs in this study may have limited the application of lung US in hematological patients with IFDs. Nevertheless, the epidemiology of IFD in hematologic patients has significantly reduced during recent years, mainly due to mould-active antifungal prophylaxis [14]. Moreover, diagnosis of IFD could be difficult in patients with neutropenia receiving mould-active antifungal prophylaxis; the clinical presentation of a pulmonary IFD may be influenced by the prophylaxis with increasing rate of atypical radiological findings non-fulfilling completely the EORTC-MSG criteria [14]. We speculate that the number of probable/proven IFD could increase by conducting larger studies in the future and developing new diagnostic tools for the diagnosis of IFD, potentially unaffected by the use of mould-active antifungal prophylaxis. However, both techniques have advantages and disadvantages, and in conclusion, they are comparable as well as complementary.

Although limited by the small number of patients included in this pilot observational study, lung US could have a significant role in the diagnostic workup and even in the follow up of lung lesions in the onco-hematological area, considering it is a bedside, reliable, rapid, and non-invasive technique. In particular, if the accuracy of lung US can be confirmed in large trials, its prompt execution could be relevant for the critical care of patients, especially considering the time and cost required for radiologic surveys.

In conclusion, our preliminary study indicates that US techniques could be potentially relevant for a multidisciplinary IFD evaluation in this high-risk population.

**SUPPLEMENTARY MATERIAL**

**Supplementary Figure 1**
Extracted US images of the 10 enrolled patients (UPN 1–10).

Click here to view
REFERENCES

1. Girmenia C, Raiola AM, Picociotti A, Algarotti A, Stanzani M, Cudillo L, Pecoraro C, Guidi S, Iori AP, Montante B, Chiusolo P, Lanino E, Carella AM, Zucchetti E, Bruno B, Irrera G, Patriarca F, Baroncioni D, Musso M, Prete A, Rusitano AM, Russo D, Mordini N, Pastore D, Vacca A, Onida F, Falcioni S, Pisapia G, Milone G, Vallisa D, Oliveri A, Bonini A, Castagnola E, Sica S, Majolino I, Bosi A, Busca A, Arcese W, Bandini G, Bacigalupo A, Rambaldi A, Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant 2014;20:872-80. PUBMED | CROSSREF

2. Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P, Einsele H, Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2005;36:757-69. PUBMED | CROSSREF

3. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, De Lochtory S, Kauffman CA, Dischmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope W, Kibbler CC, Bullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus group. Clin Infect Dis 2008;46:1813-21. PUBMED | CROSSREF

4. Metlay JP, Fine MJ. Testing strategies in the initial management of patients with community-acquired pneumonia. Ann Intern Med 2003;138:109-18. PUBMED | CROSSREF

5. Syrjälä H, Broas M, Suramo I, Ojala A, Lähde S. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis 1998;27:358-63. PUBMED | CROSSREF

6. Beckh S, Bölcskei PL, Lessnau KD. Real-time chest ultrasonography: a comprehensive review for the pulmonologist. Chest 2002;122:1759-73. PUBMED | CROSSREF

7. Lichtenstein DA, Lascols N, Meziere G, Gepner A. Ultrasound diagnosis of alveolar consolidation in the critically ill. Intensive Care Med 2004;30:276-81. PUBMED | CROSSREF

8. Greco R, Loorentino F, Morelli M, Giglio F, Mannina D, Assanelli A, Mastaglio S, Dalto S, Perini T, Lazzari L, Piromente S, Corti C, Marcatti M, Bernardi M, Lupo Stanghellini MT, Ciceri F, Peccatori J. Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation. Blood 2016;128:1528-31. PUBMED | CROSSREF

9. Cieri N, Greco R, Crucitti L, Morelli M, Giglio F, Levati G, Cervoni N, Carrabba MG, Bellio L, Milani R, Loorentino F, Stanghellini MT, De Freitas T, Markel S, Bernardi M, Corti C, Vago L, Bonini C, Ciceri F, Peccatori J. Post-transplantation cyclophosphamide and sirolimus after haploidentical hematopoietic stem cell transplantation using a treosulfan-based myeloablative conditioning and peripheral blood stem cells. Biol Blood Marrow Transplant 2015;21:1506-14. PUBMED | CROSSREF
13. Reissig A, Copetti R, Mathis G, Mempel C, Schuler A, Zechner P, Aliberti S, Neumann R, Kroegel C, Hoyer H. Lung ultrasound in the diagnosis and follow-up of community-acquired pneumonia: a prospective, multicenter, diagnostic accuracy study. Chest 2012;142:965-72.

14. Girmenia C, Busca A, Candoni A, Cesaro S, Luppi M, Nosari AM, Pagano L, Rossi G, Venditti A, Aversa F. Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management. Med Mycol 2019;57 (Suppl 2):S127-37.